December 2016
-
Inhalation experts from the Woolcock Institute of Medical Research and the University of Sydney have launched a new company called Pulmatix to provide analytical services ranging from evaluation of APIs and formulations in respiratory cells… Read more . . .
-
According to Melbourn Scientific the company has recently been awarded a Manufacturer’s/Importer’s Authorization (MIA), which allows it to act as a testing and release site for the EU. Melbourn is among the largest suppliers of… Read more . . .
-
According to AstraZeneca, data from the PATHOS real world study show fewer exacerbations and fewer hospitalizations for COPD patients treated with the Symbicort Turbuhaler than for those treated with Seretide (Advair). The study was published… Read more . . .
-
Acorda Therapeutics presented data from a Phase 1 study of its diazepam nasal spray at the American Academy of Neurology Annual Meeting this week showing that the plasma bioavailability of a 20 mg dose of… Read more . . .
-
Savara Pharmaceuticals has received additional funding for Phase 2 development of its AeroVanc vancomycin inhalation powder for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients. The company brought its Series B… Read more . . .
-
Upsher Smith presented positive Phase 1 data for its USL261 intranasal midazolam at the American Academy of Neurology (AAN) Meeting this week. The company launched a website to recruit patients for a Phase 3 study… Read more . . .
-
According to Pharmaxis, the FDA has issued a complete response letter regarding its Bronchitol inhaled mannitol for the treatment of cystic fibrosis. The company says that the FDA requested another clinical trial. The Pharmaxis press… Read more . . .
-
According to Mylan, its subsidiary Mylan Specialty L.P. has received FDA approval for its Abbreviated New Drug Application (ANDA) for levalbuterol inhalation solution, a generic version of Sunovion’s Xopenex inhalation solution. The product is used… Read more . . .
-
Pearl Therapeutics was awarded the 2013 Drug Delivery Partnerships (DDP) Innovation Award for its co-suspension formulation technology, according to the company. The company is developing several metered dose inhalation products using the technology. President and… Read more . . .
-
Alexza Pharmaceuticals has hired Peter W. Schineller as its new Senior VP and Chief Commercial Officer, responsible for global commercialization of the company’s Adasuve Staccato inhaled loxapine. The FDA approved Adasuve for the treatment of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland